Weigao Group Issues Overseas Regulatory Notice on Subsidiary’s SSE Disclosure

Shandong Weigao Group Medical Polymer Co ( (HK:1066) ) has provided an update.

Shandong Weigao Group Medical Polymer Company Limited announced that its subsidiary, Shandong Weigao Orthopaedic Device Company Limited, has published an announcement on the Shanghai Stock Exchange’s website in accordance with PRC regulatory requirements. The Hong Kong-listed parent is relaying this disclosure as an overseas regulatory announcement under Hong Kong listing rules, highlighting ongoing coordination between its dual-market regulatory obligations and providing investors with notice of developments communicated through the mainland exchange.

The announcement, dated 29 April 2026, underscores the group’s adherence to both Hong Kong and mainland Chinese disclosure standards, reflecting its cross-border capital market presence. By formally notifying shareholders and the market of the subsidiary’s publication in the Chinese section of the Shanghai Stock Exchange website, the company aims to maintain transparency, although no operational, financial, or strategic details are provided in this brief notice.

The most recent analyst rating on (HK:1066) stock is a Hold with a HK$4.00 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.

More about Shandong Weigao Group Medical Polymer Co

Shandong Weigao Group Medical Polymer Company Limited is a PRC-incorporated joint stock company listed in Hong Kong that operates in the medical devices sector. Through subsidiaries such as Shandong Weigao Orthopaedic Device Company Limited, it focuses on medical polymer products and orthopaedic devices for healthcare markets in China and abroad.

Average Trading Volume: 21,657,681

Technical Sentiment Signal: Sell

Current Market Cap: HK$16.24B

Find detailed analytics on 1066 stock on TipRanks’ Stock Analysis page.